Zelboraf Melanoma

Zelboraf - Product Information
ZELBORAF is a protein kinase inhibitor, selective for the activating mutation of the oncogenic BRAF serine-threonine kinase enzyme. Following oral dosing, the absorption rate constant for the population of metastatic melanoma patients is estimated to be 0.19 hr-1 ... Access Full Source

UNIFORM PHARMACY PRIOR AUTHORIZATION REQUEST FORM
Zelboraf in combination with ipilimumab (Yervoy) for the treatment of metastatic melanoma Zelboraf in the treatment of metastatic or unresectable papillary thyroid cancer positive for the BRAFV600 mutation ... Read More

GSK Prices Tafinlar At $7,600/month, Undercutting Roche’s ...
GlaxoSmithKline PLC is pricing its melanoma drug Tafinlar at $7,600 a month in the U.S., about GSK, GlaxoSmithKline, Tafinlar, Roche, Zelboraf, BRAF Inhibitor, FDA, melanoma, dabrafenib, pricing, reimbursement, MEK inhibitors, trametinib, metastatic melanoma, Oncology Market Access US, ... Fetch Full Source

VEMURAFENIB (ZELBORAF UTILIZATION MANAGEMENT CRITERIA
Treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as COVERAGE AUTHORIZATION CRITERIA Vemurafenib (Zelboraf) is covered for the following condition: ... Access Doc

ZELBORAF (vemurafenib)
ZELBORAF (vemurafenib) LENGTH OF AUTHORIZATION: Up to 6 months Must have a diagnosis of unresectable or metastatic melanoma with BRAFV600E mutation confirmed by BRAF testing. Medication must be prescribed by a specialist (e.g. oncologist ... Retrieve Doc

THE MELANOMA - SkinCancer.org
5 www.SkinCancer.org Vemurafenib (Zelboraf ) was the second drug approved for metastatic melanoma this year. In March, the FDA ap-proved ipilimumab (Yervoy ), a monoclonal antibody that ... Read Content

Em 17 agosto de 2011, uma dessas drogas, o Vemurafenib, foi aprovada pelo FDA para o tratamento de melanoma em estágio-final como o primeiro medicamento cuja descoberta é baseada em fragmentos moleculares. [4] Referências ... Read Article

Zelboraf - HMSA
Zelboraf Other _____ 2. What is the diagnosis? Melanoma Other _____ 3. What is the ICD9? _____ 4. Is the disease unresectable, recurrent, or metastatic? 5. Has genetic testing been performed for the BRAF mutation ... Retrieve Full Source

ZELBORAF
ZELBORAF ™ Authorization / Re Authorization 45 Earhart Drive, Suite 110, Amherst, NY 14221 Is patient diagnosed with unresectable of metastatic melanoma BRAF v600e mutation as detected by an FDA approved test? Yes No 2. ... Access Content

Xalkori And Zelboraf: The Highs And Lows Of Commercializing ...
Zelboraf helps metastatic melanoma patients with tu-mors expressing the V600 BRAF mutation and Xalkori helps non-small cell lung cancer patients with tumors expressing the EML4-ALK mutation. The two drugs were approved in ... Fetch Here

Managing ZELBORAF Side Effects - Amazon Web Services
Managing possible ZELBORAF side effects Work with your healthcare team to help manage your side effects Monitoring and managing any side effects of ZELBORAF ® (vemurafenib) tablets ... Visit Document

MediaPharm - Malignant Melanoma Therapy Gets Personal ...
The new FDA approved drug vemurafenib (Zelboraf) is offering hope for personalized treatment of one of the hardest to treat cancers. Why do I say this treatm ... View Video

Zelboraf. Prior Authorization Criteria
Zelboraf . Prior Authorization Group: Zelboraf. Drug Names: Clinically diagnosed with unresectable or metastatic melanoma with BRAF mutation. Patient received dermatologic evaluation before initiation. Electrolytes and liver enzymes are assessed ... View Doc

ZELBORAF™ (vemurafenib) 1 Of 17
ZELBORAF™ (vemurafenib) 2 of 17 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE ZELBORAF™ is indicated for the treatment of patients with unresectable or metastatic melanoma with ... Access This Document

Roche Skin Cancer Treatment Zelboraf Approved For ...
2/3 Zelboraf was the only medicine to significantly prolong survival in both previously untreated and previously treated patients with advanced melanoma. ... Doc Retrieval

About Skin Cancer
Last month, the FDA approved the drug Zelboraf (vemurafenib) for patients with melanoma, the deadliest form of skin cancer. The drug is designed to work only for late-stage melanoma patients whose tumors have a specific genetic defect known as the BRAF V600E mutation, which is present in ... Read Article

Zelboraf - YouTube
The new FDA Approved drug,called Zelboraf specifically designed for my type of melanoma, it kills the gene that it makesso we will see in the CT scan comi ... View Video

Melanoma - Wikipedia, La Enciclopedia Libre
Melanoma es el nombre genérico de los tumores melánicos o pigmentados [1] [2] (mélas (μελας gr.) En 2012 se aprobó el uso del vemurafenib, comercializado como Zelboraf, para tratar un tipo de melanoma asociado a una mutación del gen BRAF, una de las formas más malignas de esta ... Read Article

THE MELANOMA - Skin Cancer Foundation
The Melanoma Letter, A Publication of The Skin Cancer Foundation Vol. 29, No. 3, 2011 Targeting KIT for Treatment Of Advanced Melanoma, from page 1 ... Document Viewer

Interferon - Melanoma Skin Cancer Treatment With Interferon
Learn more about interferon-alfa2b, the only approved drug for the adjuvant (post-surgery) treatment of patients with high-risk melanoma in danger of recurring (coming back). ... Read Article

Hoffmann-La Roche - Wikipedia, The Free Encyclopedia
Zelboraf (vemurafenib) for late-stage V600E BRAF mutation-positive melanoma; Zenapax for the prevention of acute transplant rejection; Diabetes ... Read Article

Vemurafenib Treatment For Melanoma - About.com Health
Vemurafenib (Zelboraf ®) is a medication that targets a specific mutation found in many melanomas. Vemurafenib targets the specific V600E mutation in the BRAF protein carried by 40 to 60 percent of melanomas. This medication has shown promising results as a way to halt tumor growth temporarily ... Read Article

Roche Highlights Product Pipeline During Investor Event; Seven Major Read-outs From Clinical Trials Expected By The ...
Cotellic (cobimetinib) is currently under regulatory review in the U.S. and Europe for BRAF+ unresectable metastatic melanoma, in combination with Zelboraf (vemurafenib). Decisions from the FDA and EMA are expected in November and December, respectively. ... Read News

ZELBORAF (vemurafenib), TAFINLAR (dabrafenib)
Coverage of Zelboraf and Tafinlar will be authorized when the following apply: • The patient has a diagnosis of unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test AND • The patient is at least 18 years of age AND ... Doc Retrieval

Vemurafenib - Nature
In August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US inoperable or metastatic melanoma. Vemurafenib is priced at $9,400 per month, which corresponds to $56,400 for a 6‑month treatment course, ... Doc Retrieval

Prior Authorization Request - Zelboraf
Section B: CNS Metastases 6. Does the patient have a diagnosis of melanoma? Yes No 7. Was Zelboraf® active against the primary tumor (melanoma)? ... View Full Source